FT Options’s Amicus Therapeutics FOLD Stock Holding History

FT Options’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	$41K	Buy	+35,100	New	+$464K	0.06%	132
2017 Q1	–	Sell	-10,000	Closed	-$51K	–	316
2016 Q4	$51K	Sell	10,000 -15,000	-60%	-$104K	0.06%	135
2016 Q3	$33K	Buy	+25,000	New	+$169K	0.03%	243
2016 Q2	–	Sell	-25,000	Closed	-$9K	–	370
2016 Q1	$9K	Buy	+25,000	New	+$177K	0.01%	246

Other funds holding FOLD

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FT Options's FOLD Position: Q1 2017 in Review

FT Options sold out of Amicus Therapeutics (FOLD) in Q1 2017, closing a stake of 8,792 shares — an estimated $55.6K sold.

FT Options first reported a position in FOLD in Q4 2016 and held it in 1 quarter. The position peaked at $44K in Q4 2016. 134 funds tracked by Wall St. Rank hold FOLD as of Q1 2017.

FT Options reported no remaining Amicus Therapeutics position as of Q1 2017 after selling out during the quarter.
FT Options sold 8,792 Amicus Therapeutics shares in Q1 2017, an estimated $55.6K.
FT Options first reported a position in Amicus Therapeutics in Q4 2016 and held it in 1 quarter.
FT Options's Amicus Therapeutics position peaked at $44K in Q4 2016.
134 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.